MicroRNA153 induces apoptosis by targeting NFATc3 to improve vascular remodeling in pulmonary hypertension

References

• Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, Wikstrom G, Radegran G. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–12.doi:10.1093/eurheartj/ehx257.
   PubMed Web of Science ®Google Scholar
• He RL, Wu ZJ, Liu XR, Gui LX, Wang RX, Lin MJ. Calcineurin/NFAT signaling modulates pulmonary artery smooth muscle cell proliferation, migration and apoptosis in monocrotaline-induced pulmonary arterial hypertension rats. Cell Physiol Biochem. 2018;49(1):172–89.doi:10.1159/000492852.
   PubMedGoogle Scholar
• Xiao Y, Chen PP, Zhou RL, Zhang Y, Tian Z, Zhang SY. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis. 2020;11:1623–39.
   PubMed Web of Science ®Google Scholar
• Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003;17:2205–32.
   PubMed Web of Science ®Google Scholar
• Mak TW, Grusdat M, Duncan GS, Dostert C, Nonnenmacher Y, Cox M, Binsfeld C, Hao Z, Brustle A, Itsumi M, et al. Glutathione primes t cell metabolism for inflammation. Immunity. 2017;46:675–89.
   PubMed Web of Science ®Google Scholar
• Robinson P, Sparrow AJ, Patel S, Malinowska M, Reilly SN, Zhang YH, Casadei B, Watkins H, Redwood C. Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca(2+), and activate NFAT and Akt signaling. Am J Physiol Heart Circ Physiol. 2020;319:H306–19.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Yao J, Li Y, Xue Y, Zou Y, Shu Z, Jiao Z. Anti-apoptosis endothelial cell-secreted microRNA-195-5p promotes pulmonary arterial smooth muscle cell proliferation and migration in pulmonary arterial hypertension. J Cell Biochem. 2018;119:2144–55.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Fan K, Wang P, Yu J, Liu R, Qi H, Sun H, Cao Y. Carvacrol induces the apoptosis of pulmonary artery smooth muscle cells under hypoxia. Eur J Pharmacol. 2016;770:134–46.
   PubMed Web of Science ®Google Scholar
• Bierer R, Nitta CH, Friedman J, Codianni S, de Frutos S, Dominguez-Bautista JA, Howard TA, Resta TC, Bosc LV. NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal mice. Am J Physiol Lung Cell Mol Physiol. 2011;301:L872–80.
   PubMed Web of Science ®Google Scholar
• Chao CN, Lai CH, Badrealam KF, Lo JF, Shen CY, Chen CH, Chen RJ, Viswanadha VP, Kuo WW, Huang CY. CHIP attenuates lipopolysaccharide-induced cardiac hypertrophy and apoptosis by promoting NFATc3 proteasomal degradation. J Cell Physiol. 2019;234:20128–38.doi:10.1002/jcp.28614.
   PubMed Web of Science ®Google Scholar
• Liao MJ, Lin H, He YW, Zou C. NFATc3 deficiency protects against high fat diet (HFD)-induced hypothalamus inflammation and apoptosis via p38 and JNK suppression. Biochem Biophys Res Commun. 2018;499(4):743–50.doi:10.1016/j.bbrc.2018.03.182.
   PubMed Web of Science ®Google Scholar
• Ran Y, Wu H, Wei L, Yu X, Chen J, Li S, Zhang L, Lou J, Zhu D. NFATc3 pathway participates in the process that 15-LO/15-HETE protects pulmonary artery smooth muscle cells against apoptosis during hypoxia. Journal of Receptors and Signal Transduction. 2014;34(4):270–82.doi:10.3109/10799893.2014.917322.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hao W, Wang H. RETRACTED ARTICLE: miR-557 suppressed the malignant behaviours of osteosarcoma cells by reducing HOXB9 and deactivating the EMT process. Artif Cells Nanomed Biotechnol. 2021;49(1):230–39.doi:10.1080/21691401.2021.1890100.
   PubMed Web of Science ®Google Scholar
• Wang W, Hong G, Wang S, Gao W, Wang P. Tumor-derived exosomal miRNA-141 promote angiogenesis and malignant progression of lung cancer by targeting growth arrest-specific homeobox gene (GAX). Bioengineered. 2021;12(1):821–31.doi:10.1080/21655979.2021.1886771.
   PubMed Web of Science ®Google Scholar
• Afonso-Grunz F, Muller S. Principles of miRNA–mRNA interactions: beyond sequence complementarity. Cellular and Molecular Life Sciences. 2015;72(16):3127–41.doi:10.1007/s00018-015-1922-2.
   PubMed Web of Science ®Google Scholar
• Li Y, Wan D, Guo R, Wang F, Han L, Zhang D, Xing H, Cao W, Liu Y, Xie X, et al.Decreased bone marrow regulatory innate lymphoid cells show a distinctive miRNA profiling in aplastic anemia. Hematology. 2021;26(1):37–42.doi:10.1080/16078454.2020.1866304.
   PubMed Web of Science ®Google Scholar
• Lei S, Peng F, Li M-L, Duan W-B, Peng C-Q, Wu S-J. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2020;319(2):H377–91.doi:10.1152/ajpheart.00717.2019.
   PubMed Web of Science ®Google Scholar
• Chen WJ, Zhang EN, Zhong ZK, Jiang MZ, Yang XF, Zhou DM, Wang XW. MicroRNA-153 expression and prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(7):8671–75.
   PubMed Web of Science ®Google Scholar
• Zhao S, Deng Y, Liu Y, Chen X, Yang G, Mu Y, Zhang D, Kang J, Wu Z. MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep. 2013;40:2789–98.doi:10.1007/s11033-012-2278-4.
   PubMed Web of Science ®Google Scholar
• Zhao M, Wang W, Lu Y, Wang N, Kong D, Shan L. MicroRNA153 attenuates hypoxiainduced excessive proliferation and migration of pulmonary arterial smooth muscle cells by targeting ROCK1 and NFATc3. Mol Med Rep. 2021 23 ;194.
   PubMedGoogle Scholar
• Toba M, Alzoubi A, O’Neill KD, Gairhe S, Matsumoto Y, Oshima K, Abe K, Oka M, McMurtry IF. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats. Am J Physiol Heart Circ Physiol. 2014;306(2):H243–50.doi:10.1152/ajpheart.00728.2013.
   PubMed Web of Science ®Google Scholar
• Chen R, Yan J, Liu P, Wang Z, Wang C, Zhong W, Xu L. The role of nuclear factor of activated T cells in pulmonary arterial hypertension. Cell Cycle. 2017;16(6):508–14.doi:10.1080/15384101.2017.1281485.
   PubMed Web of Science ®Google Scholar
• Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010;121(25):2747–54.doi:10.1161/CIRCULATIONAHA.109.927681.
   PubMed Web of Science ®Google Scholar
• Feng F, Harper RL, Reynolds PN. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling. Respirology. 2016;21(3):526–32.doi:10.1111/resp.12712.
   PubMed Web of Science ®Google Scholar
• Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research. Circ Res. 2018;122(7):1021–32.doi:10.1161/CIRCRESAHA.117.312579.
   PubMed Web of Science ®Google Scholar
• Lv Y, Fu L, Zhang Z, Gu W, Luo X, Zhong Y, Xu S, Wang Y, Yan L, Li M, et al.Increased expression of microRNA-206 inhibits potassium voltage-gated channel subfamily a member 5 in pulmonary arterial smooth muscle cells and is related to exaggerated pulmonary artery hypertension following intrauterine growth retardation in rats. J Am Heart Assoc. 2019;8(2):e10456.doi:10.1161/JAHA.118.010456.
   Web of Science ®Google Scholar
• Sheak JR, Jones DT, Lantz BJ, Maston LD, Vigil D, Resta TC, Resta MM, Howard TA, Kanagy NL, Guo Y, et al.NFATc3 regulation of collagen V expression contributes to cellular immunity to collagen type V and hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2020;319(6):L968–80.doi:10.1152/ajplung.00184.2020.
   PubMed Web of Science ®Google Scholar
• Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;2:44r–58r.
   Web of Science ®Google Scholar
• Montani D, Chaumais MC, Guignabert C, Gunther S, Girerd B, Jais X, Algalarrondo V, Price LC, Savale L, Sitbon O, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014;141:172–91.
   PubMed Web of Science ®Google Scholar
• Fredenburgh LE, Ma J, Perrella MA. Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility. Trends Cardiovasc Med. 2009;19:31–37.
   PubMed Web of Science ®Google Scholar
• Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44:14–30.
   PubMed Web of Science ®Google Scholar
• Shibata A, Uchida K, Kodo K, Miyauchi T, Mikoshiba K, Takahashi T, Yamagishi H. Type 2 inositol 1,4,5-trisphosphate receptor inhibits the progression of pulmonary arterial hypertension via calcium signaling and apoptosis. Heart Vessels. 2019;34:724–34.
   PubMed Web of Science ®Google Scholar
• Liu G, Hao P, Xu J, Wang L, Wang Y, Han R, Ying M, Sui S, Liu J, Li X. Upregulation of microRNA-17-5p contributes to hypoxia-induced proliferation in human pulmonary artery smooth muscle cells through modulation of p21 and PTEN. Respir Res. 2018;19:200.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kuang M, Liu S, Hou C, Duan X, Yang K, He W, Liao J, Zheng Q, Zou G, et al. A novel rat model of pulmonary hypertension induced by mono treatment with SU5416. Hypertens Res. 2020;43:754–64.
   PubMed Web of Science ®Google Scholar
• Kojonazarov B, Hadzic S, Ghofrani HA, Grimminger F, Seeger W, Weissmann N, Schermuly RT. Severe emphysema in the SU5416/Hypoxia rat model of pulmonary hypertension. Am J Respir Crit Care Med. 2019;200:515–18.
   PubMed Web of Science ®Google Scholar
• Suen CM, Chaudhary KR, Deng Y, Jiang B, Stewart DJ. Fischer rats exhibit maladaptive structural and molecular right ventricular remodelling in severe pulmonary hypertension: a genetically prone model for right heart failure. Cardiovasc Res. 2019;115:788–99.
   PubMed Web of Science ®Google Scholar
• Friedman JK, Nitta CH, Henderson KM, Codianni SJ, Sanchez L, Ramiro-Diaz JM, Howard TA, Giermakowska W, Kanagy NL, Gonzalez BL. Intermittent hypoxia-induced increases in reactive oxygen species activate NFATc3 increasing endothelin-1 vasoconstrictor reactivity. Vascul Pharmacol. 2014;60:17–24.
   PubMed Web of Science ®Google Scholar
• de Frutos S, Diaz JM, Nitta CH, Sherpa ML, Bosc LV. Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmonary arteries. Am J Physiol Cell Physiol. 2011;301:C441–50.
   PubMed Web of Science ®Google Scholar
• Kang K, Peng X, Zhang X, Wang Y, Zhang L, Gao L, Weng T, Zhang H, Ramchandran R, Raj JU, et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem. 2013;288:25414–27.
   PubMed Web of Science ®Google Scholar
• Hao S, Jiang L, Fu C, Wu X, Liu Z, Song J, Lu H, Wu X, Li S. 2-Methoxyestradiol attenuates chronic-intermittent-hypoxia-induced pulmonary hypertension through regulating microRNA-223. J Cell Physiol. 2019;234:6324–35.
   PubMed Web of Science ®Google Scholar
• Wang LN, Yu WC, Du CH, Tong L, Cheng ZZ. Hypoxia is involved in hypoxic pulmonary hypertension through inhibiting the activation of FGF2 by miR-203. Eur Rev Med Pharmacol Sci. 2018;22:8866–76.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. Faseb J. 2009;23:4135–47.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA. 2007;104:11418–23.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Lategan J, Helmersen D. Pulmonary arterial hypertension secondary to adult-onset Still’s disease: response to cyclosporine and sildenafil over 15 years of follow-up. Respir Med Case Rep. 2016;19:27–30.
   PubMed Web of Science ®Google Scholar